The Corneal Research Group focuses on innovative solutions to restore sight and promote ocular health for a range of ocular surface diseases and conditions. With a particular interest in dry eye, stem cell repair, sutureless surgery and ocular trauma.
We are currently running clinical trials in the following areas:
To find out more information contact us on (02) 9382 7309 or email us at email@example.com.
Our novel and world-first stem cell transplantation technique, growing corneal stem cells on a contact lens (the carrier) and then transferring them to the ocular surface of the patient, has already successfully restored sight to a number of patients.
Stem cells play an important role in restoring clear vision and comfort to the surface of the eye.
Our research in this area continues, with a particular focus on the factors required to promote stem cell repair of the ocular surface.
Sutures are used to seal ocular wounds and in corneal surgery, including corneal transplantation.
Sutures, however, have a number of disadvantages, which includes infection.
Our research team has developed an innovative laser-activated chitosan bioadhesive that can be rapidly applied to the eye with high-burst pressure.
It is also capable of delivering anti-infective and anti-inflammatory agents to wounds.
Dry Eye and Blepharitis (eyelid inflammation) are common eye disorders, affecting up to 40% of people. Many of these people suffer ongoing discomfort despite available therapies, significantly impacting their quality of life.
We have developed a novel new eye drop, which provides relief whilst uniquely addressing all of the underlying aspects.Clinical trials have found decreased signs and symptoms of blepharitis and dry eye after use, treating both the cause and the symptoms of the conditions, with less side effects.
We are currently in the process of seeking funding for Phase 2 trials.
We found a link between Aromatase Inhibitors (AIs) and dry eye. AIs are the standard of care in post-menopausal women with breast cancer. We found an increase in the occurrence of dry eye in breast cancer patients compared to healthy patients.
However, we do not know what type of dry eye these women have, making it difficult to tailor interventions and develop treatments. We are now investigating whether dry eye symptoms in AI therapy are associated with clinical features of dry eye. The study will also investigate whether serum and tear levels of sex hormones are altered in AI therapy. Establishing the link between hormones and target tissue will assist in new therapeutic interventions.
This project is supported by the Ophthalmic Research Institute of Australia.
to Save Sight Institute’s mailing list for news and updates